Secarna Pharmaceuticals Appoints New Advisory Board Members

Secarna Pharmaceuticals GmbH & Co. KG, based in Martinsried, Germany, has formed an Advisory Board to enhance its strategic and financial oversight. The board includes Jens Holstein, a financial markets expert, and Richard Mark Engelhard, a shareholder representative. The Advisory Board aims to guide the company’s management in its mission to transform untreatable medical conditions into treatable ones, leveraging the AI-powered OligoCreator® platform.

CEO Konstantin Petropoulos expressed enthusiasm for the new board's potential contributions. Jens Holstein brings three decades of experience, having previously served as CFO of BioNTech SE. Richard Mark Engelhard, representing shareholder Engelhard Arzneimittel, brings industry and strategic insights to support Secarna’s growth.